HOOKIPA Pharma(US:HOOK)2022-08-17 22:39HB-200 Program in HPV16+ Cancers - HOOKIPA's HB-200 program is targeting HPV16+ cancers, addressing a large unmet medical need with 105,000 expected patient incidence in 2030[9, 10] - Phase 1 data shows 56% of patients experienced target lesion shrinkage with HB-200, and 80% disease control rate (DCR) in the 2-vector RP2D group, which is competitive compared to earlier line CPIs[20, 24] - Alternating 2-vector therapy (HB-202/HB-201) drives up to 10x higher E7/E6-specific T cell induction and amplification than 1-vector therapy[13] - 32% of patients treated with HB-202/HB-201 break the 5% threshold of tumor-specific systemic CD8+ T cells[15] - Phase 1 tolerability profile of HB-200 shows that any treatment related adverse events occurred in 63% of patients receiving HB-201 and 75% of patients receiving HB-202, with grade ≥3 events in 9% of patients[17] Pipeline Expansion - HB-300 IND in prostate cancer was cleared by the FDA in July 2022, with First Patient In (FPI) expected in Q1 2023[48, 40] - HB-700 is targeting KRAS mutant tumors, addressing sizeable clinical cancer populations[6, 37] Infectious Diseases Collaboration - Gilead is on track to file an IND for HBV in 2022, with Hookipa eligible for $190 million in development and commercialization milestones and high-single digit to mid-teen % royalties[43, 44] - HOOKIPA will progress the HIV program through a Phase 1b study with an IND in 2023, funded by $54 million from Gilead, and is eligible for $240 million in development + commercialization milestones and mid-single digit to low double-digit % royalties[43] Financial Status - As of June 30, 2022, HOOKIPA had $118 million in cash plus a Gilead equity commitment of $30 million[48]